MARAVAI Earnings Thursday, August 6, 2026 +0.25 Positive

Maravai reports Q2 2026 revenue up 9% and raises EBITDA guidance

Maravai LifeSciences reported $51.4 million in second quarter 2026 revenue and raised its full-year Adjusted EBITDA guidance, citing growth in its TriLink and Cygnus segments.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day